1545-5017/asset/MPO_centre.gif?v=1&s=8c0b4c386f6ece3ce7f8c5c02144983ee96bc8b6)
Review Article
Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?
Article first published online: 6 DEC 2007
DOI: 10.1002/pbc.21410
Copyright © 2007 Wiley-Liss, Inc.
Issue
1545-5017/asset/cover.gif?v=1&s=a75210663ec4a312a5bd8e3022f1967dde569328 "Pediatric Blood & Cancer")
Pediatric Blood & Cancer
Special Issue: Nutrition and Cancer in Children The Second International Workshop, Puebla, Mexico, November 1–5, 2006
Supplement: Puebla Workshop Supplement
Volume 50, Issue Supplement 2, pages 462–467, February 2008
Additional Information
How to Cite
Oeffinger, K. C. (2008), Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?. Pediatric Blood & Cancer, 50: 462–467. doi: 10.1002/pbc.21410
Publication History
- Issue published online: 6 DEC 2007
- Article first published online: 6 DEC 2007
- Manuscript Received: 17 SEP 2007
- Manuscript Accepted: 17 SEP 2007
- Abstract
- Article
- References
- Cited By
Keywords:
- cardiovascular;
- factors;
- risk
Abstract
Through a variety of different mechanisms, it appears that survivors of childhood acute lymphoblastic leukemia have an increased prevalence of several cardiovascular risk factors and thus are at increased risk for developing cardiovascular disease. The aim of this paper is to describe the current understanding of particular risk factors, including obesity, physical inactivity, dyslipidemia, insulin resistance, and metabolic syndrome, that may contribute to cardiovascular disease in survivors of childhood ALL. The potential roles of different cancer therapies in the development of these risk factors are discussed. In addition, two other late effects that may affect cardiovascular health are discussed: late-onset anthracycline-induced left ventricular dysfunction and methotrexate-mediated elevations of homocysteine during therapy with the potential for endothelial dysfunction. Lastly, areas needing further investigation to elucidate these risks are highlighted. Pediatr Blood Cancer 2008;50:462–467. © 2007 Wiley-Liss, Inc.